The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus
Abstract
BACKGROUND: Even after the surgical or medical treatment of hepatocellular carcinoma, tumors frequently develop at new foci, leading to a poor prognosis. OBJECTIVE: To assess whether combined tumor ablation and interferon therapy can reduce the occurrence of new foci of hepatocellular carcinoma, thereby improving survival rate. DESIGN: Randomized, controlled study. SETTING: University hospital. PATIENTS: 74 patients with compensated cirrhosis, three or fewer nodules of hepatocellular carcinoma, and low hepatitis C virus RNA loads (< or =2 x 10(6) copies/mL). INTERVENTION: After all patients had complete ablation of lesions by percutaneous ethanol injection therapy, 49 patients were assigned to receive 6 million U of interferon three times weekly for 48 weeks and 25 did not receive treatment. MEASUREMENTS: Abdominal ultrasonography, computed tomography, and determination of blood biochemical measures. RESULTS: Of the 49 patients treated with interferon, 21 showed a sustained biochemical response and 14 showed a sustained virologic response. The rate of first recurrence of new foci of hepatocellular carcinoma was similar in patients treated with interferon and untreated patients; however, the rates of second or third recurrence seemed to be lower in the interferon group than in the untreated group. Patients treated with interferon had a survival rate of 68% at 5 years and 53% at 7 years; untreated patients had a survival rate of 48% at 5 years and 23% at 7 years. CONCLUSION: After tumor ablation by ethanol injection, interferon therapy may enhance patient survival in selected patients with chronic hepatitis C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simulation study of the number of events per variable in logistic regression analysis
Peduzzi, P., Concato, J., Kemper, E., Holford, T. R., & Feinstein, A. R. (1996) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(96)00236-3 · Cited by 9,655 · cited 2×
“Patients, n 49 25 Age (range), y 61 (37–70) 63 (51–69) Sex, n Men 35 17 Women 14 8 Albumin level, gL [g/dL] 35 (32, 38) [3.”
BackgroundMazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011 · cited 1×
“Despite the clinically quiescent course of HCV infection, it may slowly progress to cirrhosis and, eventually, to hepatocellular carcinoma (1, 2).”
Classification of chronic hepatitis: Diagnosis, grading and staging
Desmet, V. J., Gerber, M., Hoofnagle, J. H., Manns, M., & Scheuer, P. J. (1994) · Hepatology · doi:10.1002/hep.1840190629 · Cited by 2,593
Small Hepatocellular Carcinoma: Treatment with Radio-frequency Ablation versus Ethanol Injection
Livraghi, T., Goldberg, S. N., Lazzaroni, S., Meloni, F., Solbiati, L., & Gazelle, G. S. (1999) · Radiology · doi:10.1148/radiology.210.3.r99fe40655 · Cited by 1,283
Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M.-H., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392102 · Cited by 1,282
Terminology of nodular hepatocellular lesions
Wanless, I. R. (1995) · Hepatology · doi:10.1002/hep.1840220341 · Cited by 1,130
Risk Factors for Hepatocellular Carcinoma among Patients with Chronic Liver Disease
Tsukuma, H., Hiyama, T., Tanaka, S., Nakao, M., Yabuuchi, T., Kitamura, T., Nakanishi, K., Fujimoto, I., Inoue, A., Yamazaki, H., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282501 · Cited by 1,126
Cited by
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
Self-citationOmata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Self-citationNovel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Percutaneous radiofrequency ablation for hepatocellular carcinoma: An analysis of 1000 cases
Tateishi, R., Shiina, S., Teratani, T., Obi, S., Sato, S., Koike, Y., Fujishima, T., Yoshida, H., Kawabe, T., & Omata, M. (2005) · Cancer · doi:10.1002/cncr.20892 · Cited by 778
Self-citationUpdated treatment approach to hepatocellular carcinoma
Llovet, J. M. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-005-1566-3 · Cited by 508
Metadata
- Authors
- Shiratori, Y., Shiina, S., Teratani, T., Imamura, M., Obi, S., Sato, S., Koike, Y., Yoshida, H., & Omata, M.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2003-02-18
- Volume
- 138
- Issue
- 4
- Pages
- 299-306
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1987689694
- Cited by
- 274
- References
- 32
- FWCI
- 14.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus. https://app.cochat.ai/papers/10.7326/0003-4819-138-4-200302180-00008
- The paper
- Shiratori, Y., Shiina, S., Teratani, T., Imamura, M., Obi, S., Sato, S., Koike, Y., Yoshida, H., & Omata, M. (2003). Interferon Therapy after Tumor Ablation Improves Prognosis in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-138-4-200302180-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.